BOSTON, March 14 /PRNewswire/ -- AdipoGenix Inc., a biopharmaceutical
company developing small molecule therapies for obesity, type 2 diabetes and
associated morbidities, today announced the achievement of its third milestone
in the Company's drug discovery collaboration with Johnson & Johnson (J&J).
In November 2002, AdipoGenix and J&J entered a drug discovery
collaboration in which AdipoGenix has utilized its proprietary human fat cell-
based technologies for discovering compounds that reduce the fat content of
human fat cells from J&J's compound collection. In addition, AdipoGenix has
been characterizing the mechanisms of action and identifying molecular targets
for the highest priority of the active compounds that were discovered. The
milestone announced today was for the successful identification of the
molecular target for one of J&J's active compounds that was discovered earlier
in the collaboration. Financial details were not disclosed.
"This is the third milestone that we have achieved in our alliance with
J&J, and this achievement provides further validation for our capability to
discover compounds that have a beneficial effect on fat cells, and to define
mechanisms and molecular targets for active compounds," said Ed Cannon, Ph.D.,
CEO of AdipoGenix.
Monique Berwaer, Principal Scientist and Metabolic Diseases Team Leader,
Johnson & Johnson Pharmaceutical Research and Development commented,
"AdipoGenix's human fat cell-based discovery technology is unique and we
believe that treating obesity by targeting human fat with pharmaceuticals that
reduce fat content is distinctive and an important new approach for combating
the growing obesity epidemic."
AdipoGenix Technology
AdipoGenix's core assets and capabilities include a proprietary and
diverse collection of human fat cell precursors from all relevant fat
deposits, a high-throughput discovery technology for differentiating these
precursor cells to form mature human fat cells and identifying compounds that
reduce the fat content of human fat cells, a portfolio of assays and
pharmacologic tools to identify the mechanism of action and molecular targets
for active compounds identified, and proprietary lead compounds. With this
comprehensive approach, AdiopGenix has been able to rapidly identify non-toxic
small molecule compounds that target the pathological tissue (fat) from the
relevant organism (humans) and produce the desired therapeutic outcome (less
fat).
About AdipoGenix Inc.
AdipoGenix is a Boston-based biopharmaceutical company developing
pharmaceuticals that target human fat tissue to treat obesity and its co-
morbidities, including diabetes and cardiovascular disease. Through its
proprietary human fat cell-based technology, AdipoGenix identifies nontoxic,
small molecule compounds that reduce the fat content in human fat tissue,
which is expected to provide therapeutic benefit for these important diseases.
On the Net: http://www.AdipoGenix.com
Contacts:
Ed Cannon Kari Watson
President and CEO MacDougall Biomedical Communications
AdipoGenix Inc. (508) 647-0209
617-638-6394 kwatson@macbiocom.com
SOURCE AdipoGenix Inc.
 back to top
Related links:
http://www.AdipoGenix.com
CONTACT:
Ed Cannon, President and CEO of AdipoGenix
Inc., +1-617-638- 6394; or Kari Watson of MacDougall Biomedical
Communications, +1-508-647-0209, kwatson@macbiocom.com
|
